Loading...
•
Mar 31, 2020
Vanda Q1 2020 Earnings Report
Reported strong financial performance with increased total revenues and net income.
Key Takeaways
Vanda Pharmaceuticals reported a strong first quarter in 2020, with a 22% increase in total revenues year-over-year, reaching $58.0 million. The company also achieved net income of $0.5 million, a significant improvement compared to the net loss of $0.6 million in the first quarter of 2019.
Total net product sales reached $58.0 million, a 22% increase year-over-year.
HETLIOZ® net product sales were $35.3 million, a 22% increase year-over-year.
Fanapt® net product sales were $22.7 million, a 21% increase year-over-year.
Cash, cash equivalents, and marketable securities were $312.3 million as of March 31, 2020.
Revenue by Segment
Forward Guidance
Vanda will continue to assess the impact of the rapidly evolving COVID-19 pandemic on its business and operations and will provide future updates to its financial guidance as necessary.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...